Amendments have been approved by the Australian Government regulator to the TGA guidelines under Therapeutic Goods Order 104, 2019 to allow listed disinfectants to make validated claims to kill the COVID-19 virus on surfaces.
The new arrangements were uploaded to the Australian Therapeutic Goods Administration (TGA) website on Monday, 23 March 2020.
Dr Greg Whiteley, chairman for Whiteley Corporation, said the outcome was a great example of collaboration in a time of national and international crisis with the COVID-19 pandemic.
“The TGA worked with the peak industry association, Accord Australasia, to negotiate a pragmatic approach that will assist in alleviating public health concerns over the risk of the spread of the virus via hospital and medical surfaces.
“The TGA and Accord leadership are to be congratulated on the speedy outcome of this change process which will benefit all of the Australian medical community and the medical manufacturing sector. This new technical arrangement will allow improved certainty around disinfecting surfaces within healthcare settings,” Whiteley said.
“We would like to note particular thanks to Adjunct Professor John Skerritt and the entire team inside the TGA, and also to Bronwyn Capanna, executive director of Accord Australasia and her team at Accord for achieving this outcome.”
Whiteley said there are continuing negotiations on further improvements around other vital infection prevention technologies.
“This collaborative process allows Australians to have increased levels of certainty around the health and hygiene standards within Australian hospitals and healthcare providers.”
Comment below to have your say on this story.
If you have a news story or tip-off, get in touch at firstname.lastname@example.org.
Sign up to INCLEAN’s newsletter.